Lesson plan

SPV-400

SPV-400 is a tropomyosin receptor kinase B (TrkB) agonist which is under development for the treatment of neurological disorders. It is taken parenterally. The preclinical pharmacokinetics of SPV-400 have been studied and described. The drug is under development by Spave Science. As of August 2025, it is in the preclinical research stage of development for neurological disorders. The chemical structure of SPV-400 does not yet appear to have been disclosed.

Back to article

Article summary

SPV-400 is a tropomyosin receptor kinase B (TrkB) agonist which is under development for the treatment of neurological disorders. It is taken parenterally. The preclinical pharmacokinetics of SPV-400 have been studied and described. The drug is under development by Spave Science. As of August 2025, it is in the preclinical research stage of development for neurological disorders. The chemical structure of SPV-400 does not yet appear to have been disclosed.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.